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In recent years, stem cell therapy has become a very talented and advanced scientific research topic. The progress of treatment methods has 
induced great potentials. This paper is a review focused on the discovery of different stem cells and the potential therapies based on these cells. 
The beginning of stem cells is tracked by laboratory steps of skillful stem cell culturing and origin. Quality control and teratoma development 
assays are essential procedures in assessing the properties of the stem cells tested. Derivation methods and the application of culturing media 
are crucial to set correct environmental conditions for controlled distinction. Among many types of stem tissue applications, the use of graphene 
scaffolds and the potential of extracellular vesicle-based therapies require consideration due to their versatility. Challenges summarize the 
review that stem cell therapy must overcome to be accepted wide-reaching. A wide variety of possibilities makes this cutting-edge therapy a 
turning point in modern medicine, providing hope for permanent diseases.
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IntroductIon
Stem cells are unspecialized cells of the human body. They are 
able to distinguish into any cell of an organism and have the ability 
of self-renewal. Stem cells exist both in embryos and adult cells. 
There are several steps to specialization. Developmental potency is 
reduced with each step, which means that a unipotent stem cell is 
not able to separate into as many types of cells as a pluripotent one. 
Totipotent stem cells are able to divide and discriminate 
into cells of the whole organism. Totipotency has the highest 
differentiation potential and allows cells to form both embryo and 
extra-embryonic structures. One example of a totipotent cell is a 
zygote, which is formed after a sperm fertilizes an egg. These cells 
can later grow either into any of the three germ layers or form a 
placenta. After approximately 4  days, the blastocyst’s inner cell 
mass becomes pluripotent. 
Pluripotent stem cells (PSCs) form cells of all germ layers but 
not extraembryonic structures, such as the placenta. Embryonic 
stem cells (ESCs) are an example. ESCs are consequential from the 
inner cell mass of preimplantation embryos. Another example is 
induced pluripotent stem cells (iPSCs) resultant from the epiblast 
layer of implanted embryos. Their pluripotency is a continuum, 
opening from completely pluripotent cells such as ESCs and iPSCs 
and ending on councils with less potencymulti-, oligo- or unipotent 
cells. One of the methods to evaluate their activity and spectrum is 
the teratoma formation assay. iPSCs are affectedly generated from 
somatic cells, and they function similarly to PSCs. Their culturing 
and utilization are very promising for present and future reformative 
medicine.
Multipotent stem cells have a thinner spectrum of differentiation 
than PSCs, but they can specify in separate cells of specific cell lines. 
One example is a haematopoietic stem cell, which can mature into 
several types of blood cells. After diversity, a haematopoietic stem 
cell converts an oligopotent cell. Its variation abilities are then 
restricted to cells of its lineage. However, some multipotent cells 
are capable of adaptation into dissimilar cell types, which suggests 
naming them pluripotent cells. Oligopotent stem cells can separate 
into several cell types. A myeloid stem cell is an example that can 
split into white blood cells but not red blood cells. Unipotent stem 
cells are considered by the narrowest differentiation capabilities and 
special property of dividing recurrently. Their latter feature makes 
them a promising candidate for therapeutic use in regenerative 
medicine. These cells are only able to form one cell type, e.g., 
dermatophytes.
Stem cell biology
A blastocyst is designed after the fusion of sperm and ovum 
fertilization. Its inner wall is lined with passing stem cells, namely, 
embryonic stem cells. Blastocysts are collected of two distinct 
cell types: the inner cell mass (ICM), which develops into epiblasts 
and induces the development of a fetus, and the trophectoderm 
(TE). Blastocysts are responsible for the regulation of the ICM 
microenvironment. The TE continues to mature and forms the 
extraembryonic support structures needed for the successful origin 
of the embryo, such as the placenta. As the TE begins to form a 
specialized support structure, the ICM cells remain undifferentiated, 
fully pluripotent and proliferative.1 The pluripotency of stem cells 
allows them to form any cell of the organism. Human embryonic 
stem cells (hESCs) are derived from the ICM. During the process 
of embryogenesis, cells form aggregations called germ layers: 
endoderm, mesoderm and ectoderm, each eventually giving rise 
to differentiated cells and tissues of the foetus and, later on, the 
adult animal.2 After hESCs distinguish into one of the germ layers, 
they become multipotent stem cells, whose potency is limited 
to only the cells of the germ layer. This process is short in human 
development. After that, pluripotent stem cells occur all over the 
organism as indistinguishable cells, and their key abilities are 
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.
org/licenses/by/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to 
the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain 
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
A Review on the Discovery of Different Stem Cells and the Potential Therapies based on these Cells
International Journal of Health and Biological Sciences, Oct-Dec, 2019; 2(4) 7
proliferation by the formation of the next generation of stem cells 
and distinction into specialized cells under certain physiological 
circumstances.
Recognition by morphological differences
The comparability of stem cell lines from different entities is needed 
for iPSC lines to be used in therapeutics.3 Among critical quality 
procedures, the following can be eminent:
Short tandem repeat analysis—This is the comparison of 
specific loci on the DNA of the samples. It is used in measuring 
an exact number of repeating units. One unit consists of 2 to 13 
nucleotides repeating many times on the DNA strand. A polymerase 
chain reaction is used to check the lengths of short tandem repeats. 
The genotyping procedure of source tissue, cells, and iPSC seed and 
master cell banks is recommended.
Identity analysis—The unintentional switching of lines, 
resulting in other stem cell line adulteration, requires rigorous assay 
for cell line documentation.
Residual vector testing—An appearance of reprogramming 
vectors integrated into the host genome is hazardous, and testing 
their presence is a mandatory procedure. It is a commonly used 
procedure for generating high-quality iPSC lines. An acceptable 
threshold in high-quality research-grade iPSC line collections is 
≤ 1 plasmid copies per 100 cells. During the procedure, 2 different 
regions, common to all plasmids, should be used as specific targets, 
such as EBNA and CAG sequences.3 To accurately represent the 
test reactions, a standard curve needs to be prepared in a carrier 
of gDNA from a well-characterized hPSC line. For calculations of 
plasmid copies per cell, it is crucial to incorporate internal reference 
gDNA sequences to allow the quantification of, for example, 
ribonuclease P (RNaseP) or human telomerase reverse transcriptase 
(hTERT).
Karyotype—A long-term culture of hESCs can accumulate 
culture-driven mutations.4 Because of that, it is critical to pay 
additional attention to genomic integrity. Karyotype tests can be 
performed by resuscitating characteristic aliquots and culturing 
them for 48–72 h before harvesting cells for karyotypic analysis. If 
abnormalities are found within the first 20 karyotypes, the analysis 
must be repeated on a fresh sample. When this situation is repetitive, 
the line is evaluated as abnormal. Repeated abnormalities must be 
recorded. Although karyology is a crucial procedure in stem cell 
quality control, the single nucleotide polymorphism (SNP) array, 
conversed later, has approximately 50 times higher resolution.
Viral testing—When assessing the quality of stem cells, all tests 
for harmful human adventitious agents must be performed (e.g. 
hepatitis C or human immunodeficiency virus). This procedure must 
be performed in the e of non-xeno-free culture agents.
Bacteriology—Bacterial or fungal sterility tests can be divided 
into culture- or broth-based tests. All the procedures must be 
recommended by pharmacopoeia for the jurisdiction in which the 
work is performed.
Single nucleotide polymorphism arrays—This procedure is a 
type of DNA microarray that detects population polymorphisms by 
enabling the detection of subchromosomal changes and the copy-
neutral loss of heterozygosity, as well as an indication of cellular 
conversion. The SNP assay consists of three components. The first is 
labelling fragmented nucleic acid sequences with fluorescent dyes. 
The second is an array that contains immobilized allele-specific 
oligonucleotide (ASO) probes. The last component detects, records, 
and finally interprets the signal.
Flow cytometry—This is a practice that utilizes light to count and 
profile cells in a heterogeneous fluid mixture. It allows researchers 
to accurately and rapidly collect data from heterogeneous fluid 
mixtures with live cells. Cells are passed through a narrow channel 
one by one. During light illumination, sensors detect light emitted 
or refracted from the cells. The last step is data analysis, compilation 
and integration into a comprehensive picture of the trial.
Phenotypic pluripotency assays—Recognizing undifferentiated 
cells is crucial in successful stem cell therapy. Among other 
characteristics, stem cells appear to have a distinct morphology with 
a high nucleus to cytoplasm ratio and a prominent nucleolus. Cells 
appear to be flat with defined borders, in contrast to differentiating 
colonies, which look as loosely located cells with rough borders.5 
It is important that images of ideal and poor-quality colonies for 
each cell line are kept in laboratories, so whenever there is doubt 
about the quality of culture, it can always be checked according to 
the representative image. Embryoid body formation or directed 
diversity of monolayer cultures to produce cell types representative 
of all three embryonic germ layers must be performed. It is 
important to note that colonies cultured under different conditions 
may have different morphologies.6
Histone modification and DNA methylation—Quality control 
can be achieved by using epigenetic analysis tools such as histone 
modification or DNA methylation. When stem cells differentiate, 
the methylation process silences pluripotency genes, which 
reduces differentiation potential, although other genes may 
undergo demethylation to become expressed.7 It is important to 
emphasize that stem cell identity, together with its morphological 
characteristics, is also related to its epigenetic profile. 8,9 According 
to Brindley,10 there is a relationship between epigenetic changes, 
pluripotency, and cell expansion conditions, which emphasizes that 
unmethylated regions appear to be serum-dependent.
Turning point in stem cell therapy
The turning point in stem cell therapy appeared in 2006, when 
scientists Shinya Yamanaka, together with Kazutoshi Takahashi, 
discovered that it is possible to reprogram multipotent adult stem 
cells to the pluripotent state. This procedure avoided endangering 
the foetus’ life in the process. Retrovirus-mediated transduction 
of mouse fibroblasts with four transcription factors (Oct-3/4, Sox2, 
KLF4, and c-Myc)34 that are mainly stated in embryonic stem cells 
could induce the fibroblasts to become pluripotent.35 This new 
form of stem cells was named iPSCs. One year later, the experiment 
also succeeded with human cells.36 After this success, the method 
opened a new field in stem cell research with a generation of iPSC 
lines that can be customized and biocompatible with the patient. 
Recently, studies have focused on reducing carcinogenesis and 
improving the transfer system.Retroviral-mediated transduction 
induces pluripotency in isolated patient somatic cells. Target cells 
lose their role as somatic cells and, once again, become pluripotent 
and can differentiate into any cell type of human body. The turning 
point was influenced by former discoveries that happened in 1962 
and 1987.The former discovery was about scientist John Gurdon 
successfully cloning frogs by relocating a nucleus from a frog’s 
somatic cells into an oocyte. This caused a complete reversion of 
somatic cell development.37 It is even possible for a somatic cell 
to again acquire pluripotency.38 The latter was a discovery made 
by Davis R.L. that focused on fibroblast DNA subtraction. Three 
genes were found that originally appeared in myoblasts. The 
enforced expression of only one of the genes, named myogenic 
distinction 1 (Myod1), caused the conversion of fibroblasts 
into myoblasts, showing that reprogramming cells is possible, 
and it can even be used to transform cells from one lineage to 
another.39
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Directed differentiation
To be useful in therapy, stem cells must be changed into desired 
cell types as necessary or else the whole regenerative medicine 
process will be pointless. Differentiation of ESCs is crucial because 
undifferentiated ESCs can cause teratoma formation in vivo. 
Understanding and using signalling pathways for differentiation 
is an important method in successful regenerative medicine. In 
directed differentiation, it is likely to mimic signals that are received 
by cells when they undergo successive stages of development.51 
The extracellular microenvironment plays a significant role in 
controlling cell behaviour. By manipulating the culture conditions, it 
is possible to restrict specific differentiation pathways and generate 
cultures that are enriched in certain precursors in vitro. However, 
achieving a similar effect in vivo is challenging. It is crucial to develop 
culture conditions that will allow the promotion of homogenous 
and enhanced differentiation of ESCs into functional and desired 
tissues.
Regarding the self-renewal of embryonic stem cells, Hwang et 
al. [52] noted that the ideal culture method for hESC-based cell and 
tissue therapy would be a defined culture free of either the feeder 
layer or animal components. This is because cell and tissue therapy 
require the maintenance of large quantities of undifferentiated 
hESCs, which does not make feeder cells suitable for such tasks.
Most directed differentiation protocols are formed to mimic 
the development of an inner cell mass during gastrulation. During 
this process, pluripotent stem cells differentiate into ectodermal, 
mesodermal, or endodermal progenitors. Mall molecules or 
growth factors induce the conversion of stem cells into appropriate 
progenitor cells, which will later give rise to the desired cell type. 
There is a variety of signal intensities and molecular families 
that may affect the establishment of germ layers in vivo, such as 
fibroblast growth factors (FGFs);53 the Wnt family54 or superfamily 
of transforming growth factors—β(TGFβ); and bone morphogenic 
proteins (BMP).55 Each candidate factor must be tested on various 
concentrations and additionally applied to various durations 
because the precise concentrations and times during which 
developing cells in embryos are influenced during differentiation 
are unknown. For instance, molecular antagonists of endogenous 
BMP and Wnt signalling can be used for ESC formation of 
ectoderm.56 However, transient Wnt and lower concentrations of 
the TGFβ family trigger mesodermal differentiation.57 Regarding 
endoderm formation, a higher activin A concentration may be 
required.58,59 There are numerous protocols about the methods 
of forming progenitors of cells of each of germ layers, such as 
cardiomyocytes,60 hepatocytes,61 renal cells,62 lung cells,63,64 motor 
neurons,65 intestinal cells,66 or chondrocytes.67
Directed differentiation of either iPSCs or ESCs into, e.g. 
hepatocytes, could influence and develop the study of the 
molecular mechanisms in human liver development. In addition, it 
could also provide the possibility to form exogenous hepatocytes 
for drug toxicity testing.68 Levels of concentration and duration of 
action with a specific signalling molecule can cause a variety of 
factors. Unfortunately, for now, a high cost of recombinant factors 
is likely to limit their use on a larger scale in medicine. The more 
promising technique focuses on the use of small molecules. These 
can be used for either activating or deactivating specific signalling 
pathways. They enhance reprogramming efficiency by creating cells 
that are compatible with the desired type of tissue. It is a cheaper 
and non-immunogenic method.
One of the successful examples of small-molecule cell therapies 
is antagonists and agonists of the Hedgehog pathway. They show to 
be very useful in motor neuron regeneration.69 Endogenous small 
molecules with their function in embryonic development can also 
be used in in vitro methods to induce the differentiation of cells; 
for example, retinoic acid, which is responsible for patterning the 
nervous system in vivo,70 surprisingly induced retinal cell formation 
when the laboratory procedure involved hESCs.71
The efficacy of differentiation factors depends on functional 
maturity, efficiency, and, finally, introducing produced cells to 
their in vivo equivalent. Topography, shear stress, and substrate 
rigidity are factors influencing the phenotype of future cells.72 The 
control of biophysical and biochemical signals, the biophysical 
environment, and a proper guide of hESC differentiation are 
important factors in appropriately cultured stem cells.
Stem cell utilization and their manufacturing 
standards and culture systems
The European Medicines Agency and the Food and Drug 
Administration have set Good Manufacturing Practice (GMP) 
guidelines for safe and appropriate stem cell transplantation. In the 
past, protocols used for stem cell transplantation required animal-
derived products.73 The risk of introducing animal antigens or 
pathogens caused a restriction in their use. Due to such limitations, 
the technique required an obvious update.74 Now, it is essential 
to use xeno-free equivalents when establishing cell lines that are 
derived from fresh embryos and cultured from human feeder 
cell lines.75 In this method, it is crucial to replace any non-human 
materials with xeno-free equivalents.76 NutriStem with LN-511, 
TeSR2 with human recombinant laminin (LN-511), and RegES with 
human foreskin fibroblasts (HFFs) are commonly used xeno-free 
culture systems.33 There are many organizations and international 
initiatives, such as the National Stem Cell Bank, that provide stem 
cell lines for treatment or medical research.77
Stem cell use in medicine
Stem cells have great potential to become one of the most 
important aspects of medicine. In addition to the fact that they 
play a large role in developing restorative medicine, their study 
reveals much information about the complex events that happen 
during human development.
The difference between a stem cell and a differentiated cell 
is reflected in the cells’ DNA. In the former cell, DNA is arranged 
loosely with working genes. When signals enter the cell and the 
differentiation process begins, genes that are no longer needed 
are shut down, but genes required for the specialized function 
will remain active. This process can be reversed, and it is known 
that such pluripotency can be achieved by interaction in gene 
sequences. Takahashi and Yamanaka78 and Loh et al.79 discovered 
that octamer-binding transcription factor 3 and 4 (Oct3/4), sex 
determining region Y (SRY)-box 2 and Nanog genes function as 
core transcription factors in maintaining pluripotency. Among 
them, Oct3/4 and Sox2 are essential for the generation of iPSCs.
Many serious medical conditions, such as birth defects or 
cancer, are caused by improper differentiation or cell division. 
Currently, several stem cell therapies are possible, among which 
are treatments for spinal cord injury, heart failure,80 retinal and 
macular degeneration,81 tendon ruptures, and diabetes type 1.82 
Stem cell research can further help in better understanding stem 
cell physiology. This may result in finding new ways of treating 
currently incurable diseases.
Haematopoietic stem cell transplantation
Haematopoietic stem cells are important because they are by far 
the most thoroughly characterized tissue-specific stem cell; after 
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all, they have been experimentally studied for more than 50 years. 
These stem cells appear to provide an accurate paradigm model 
system to study tissue-specific stem cells, and they have potential 
in regenerative medicine.
Multipotent haematopoietic stem cell (HSC) transplantation 
is currently the most popular stem cell therapy. Target cells are 
usually derived from the bone marrow, peripheral blood, or 
umbilical cord blood.83 The procedure can be autologous (when 
the patient’s own cells are used), allogenic (when the stem cell 
comes from a donor), or syngeneic (from an identical twin). HSCs 
are responsible for the generation of all functional haematopoietic 
lineages in blood, including erythrocytes, leukocytes, and 
platelets. HSC transplantation solves problems that are caused by 
inappropriate functioning of the haematopoietic system, which 
includes diseases such as leukaemia and anaemia. However, when 
conventional sources of HSC are taken into consideration, there 
are some important limitations. First, there is a limited number 
of transplantable cells, and an efficient way of gathering them 
has not yet been found. There is also a problem with finding 
a fitting antigen-matched donor for transplantation, and viral 
contamination or any immunoreactions also cause a reduction in 
efficiency in conventional HSC transplantations. Haematopoietic 
transplantation should be reserved for patients with life-
threatening diseases because it has a multifactorial character and 
can be a dangerous procedure. iPSC use is crucial in this procedure. 
The use of a patient’s own unspecialized somatic cells as stem cells 
provides the greatest immunological compatibility and significantly 
increases the success of the procedure.
Stem cells as a target for pharmacological testing
Stem cells can be used in new drug tests. Each experiment on living 
tissue can be performed safely on specific differentiated cells from 
pluripotent cells. If any undesirable effect appears, drug formulas 
can be changed until they reach a sufficient level of effectiveness. 
The drug can enter the pharmacological market without harming 
any live testers. However, to test the drugs properly, the conditions 
must be equal when comparing the effects of two drugs. To achieve 
this goal, researchers need to gain full control of the differentiation 
process to generate pure populations of dif ferentiated 
cells.
Stem cells as an alternative for arthroplasty
One of the biggest fears of professional sportsmen is getting an 
injury, which most often signifies the end of their professional 
career. This applies especially to tendon injuries, which, due to 
current treatment options focusing either on conservative or 
surgical treatment, often do not provide acceptable outcomes. 
Problems with the tendons start with their regeneration capabilities. 
Instead of functionally regenerating after an injury, tendons merely 
heal by forming scar tissues that lack the functionality of healthy 
tissues. Factors that may cause this failed healing response include 
hypervascularization, deposition of calcific materials, pain, or 
swelling.84
Additionally, in addition to problems with tendons, there is 
a high probability of acquiring a pathological condition of joints 
called osteoarthritis (OA).85 OA is common due to the avascular 
nature of articular cartilage and its low regenerative capabilities.86 
Although arthroplasty is currently a common procedure in treating 
OA, it is not ideal for younger patients because they can outlive 
the implant and will require several surgical procedures in the 
future. These are situations where stem cell therapy can help by 
stopping the onset of OA.87 However, these procedures are not well 
developed, and the long-term maintenance of hyaline cartilage 
requires further research.
Osteonecrosis of the femoral hip (ONFH) is a refractory 
disease associated with the collapse of the femoral head and risk 
of hip arthroplasty in younger populations.88 Although total hip 
arthroplasty (THA) is clinically successful, it is not ideal for young 
patients, mostly due to the limited lifetime of the prosthesis. An 
increasing number of clinical studies have evaluated the therapeutic 
effect of stem cells on ONFH. Most of the authors demonstrated 
positive outcomes, with reduced pain, improved function, or 
avoidance of THA.89,90,91
Rejuvenation by cell programming
Ageing is a reversible epigenetic process. The first cell rejuvenation 
study was published in 2011.92 Cells from aged individuals have 
different transcriptional signatures, high levels of oxidative stress, 
dysfunctional mitochondria, and shorter telomeres than in young 
cells.93 There is a hypothesis that when human or mouse adult 
somatic cells are reprogrammed to iPSCs, their epigenetic age is 
virtually reset to zero.94 This was based on an epigenetic model, 
which explains that at the time of fertilization, all marks of parenteral 
ageing are erased from the zygote’s genome and its ageing clock 
is reset to zero.95
In their study, Ocampo et al.96 used Oct4, Sox2, Klf4, and 
C-myc genes (OSKM genes) and affected pancreas and skeletal 
muscle cells, which have poor regenerative capacity. Their 
procedure revealed that these genes can also be used for effective 
regenerative treatment.97 The main challenge of their method 
was the need to employ an approach that does not use transgenic 
animals and does not require an indefinitely long application. The 
first clinical approach would be preventive, focused on stopping 
or slowing the ageing rate. Later, progressive rejuvenation of old 
individuals can be attempted. In the future, this method may raise 
some ethical issues, such as overpopulation, leading to lower 
availability of food and energy.
For now, it is important to learn how to implement cell 
reprogramming technology in non-transgenic elder animals and 
humans to erase marks of ageing without removing the epigenetic 
marks of cell identity.
conclusIon
After several decades of experiments, stem cell therapy is becoming 
a wonderful game changer for medicine. With each experiment, the 
capabilities of stem cells are growing, although there are still many 
obstacles to overcome. Regardless, the influence of stem cells in 
regenerative medicine and transplantology is immense. Currently, 
permanent neurodegenerative diseases have the possibility of 
becoming treatable with stem cell therapy. Induced pluripotency 
enables the use of a patient’s own cells. Tissue banks are becoming 
progressively popular, as they gather cells that are the source of 
regenerative medicine in a struggle against present and future 
diseases. With stem cell therapy and all its regenerative benefits, we 
are improved able to prolong human life than at any time in history.
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